<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01327807</url>
  </required_header>
  <id_info>
    <org_study_id>CCIR100913</org_study_id>
    <nct_id>NCT01327807</nct_id>
  </id_info>
  <brief_title>Cure Cystinosis International Registry</brief_title>
  <acronym>CCIR</acronym>
  <official_title>Cure Cystinosis International Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cystinosis Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cystinosis Research Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cure Cystinosis International Registry (CCIR) is an online, patient self-identifying registry&#xD;
      developed by medical and scientific experts specifically for the cystinosis community.&#xD;
&#xD;
      CCIR's sole purpose is to identify people with cystinosis worldwide in an effort to&#xD;
      accelerate novel treatments and a cure for cystinosis.&#xD;
&#xD;
      CCIR provides a safe and secure platform for:&#xD;
&#xD;
        -  sharing anonymous medical information about cystinosis with researchers, clinicians and&#xD;
           patients&#xD;
&#xD;
        -  disseminating information about research opportunities&#xD;
&#xD;
        -  connecting researchers/investigators and prospective participants *&#xD;
&#xD;
      Interested cystinosis patients may register themselves with CCIR online at&#xD;
      http://www.cystinosisregistry.org.&#xD;
&#xD;
      * No personal information is shared outside of CCIR. Individual identities are known only to&#xD;
      appropriate CCIR staff. If a participant is matched to a clinical trial, the participant&#xD;
      receives a notice from CCIR, after which they can decide whether they wish to contact the&#xD;
      study sponsor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Significance and Purpose:&#xD;
&#xD;
      Many different resources and tools are necessary to make significant advances in medical&#xD;
      research. Progress in rare diseases such as cystinosis can often be impeded by the lack of&#xD;
      information available about the disease and limited access to volunteers eligible for&#xD;
      clinical trials. Therefore, patients who are willing to provide information about how the&#xD;
      disease has affected them and also make themselves available to participate in trials are&#xD;
      among the most valuable resources the investigators have to fight a disease. However, the&#xD;
      research community desperately needs the right tool that will permit access to these&#xD;
      resources.&#xD;
&#xD;
      A tool widely used to conveniently collect both data about a disease and information about&#xD;
      potential clinical trial participants is a patient registry. A patient registry is any system&#xD;
      that allows for the organized collection of data about disease outcomes in affected&#xD;
      populations for a scientific, clinical, or policy purpose. The Cystinosis Research Foundation&#xD;
      (CRF) has aligned itself with cystinosis medical experts and organizations worldwide to&#xD;
      create the first ever international, online patient registry for cystinosis, Cure Cystinosis&#xD;
      International Registry (CCIR). The express purpose of CCIR is to make anonymous information&#xD;
      available to the research community and thus promote accelerated research in advanced&#xD;
      treatments and ultimately a cure for cystinosis.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      The objectives of CCIR are:&#xD;
&#xD;
        -  Evaluate epidemiology and clinical characteristics of cystinosis around the world.&#xD;
&#xD;
        -  Evaluate and compare the diagnosis, treatment, and kidney transplant rates among&#xD;
           cystinosis communities from different geographical areas.&#xD;
&#xD;
        -  Enhance the understanding of how cystinosis affects quality of life.&#xD;
&#xD;
      CCIR Registration:&#xD;
&#xD;
      Interested cystinosis patients may register themselves with CCIR online at&#xD;
      http://www.cystinosisregistry.org. Registration is easy and secure. Simply go to the website&#xD;
      and create a CCIR account and complete a survey. The CCIR website is currently available in&#xD;
      English and Spanish, and will soon be available in French, Portuguese, and possibly other&#xD;
      languages.&#xD;
&#xD;
      Benefits to CCIR participants include instant access to the registry's accumulated survey&#xD;
      results (reported as anonymous group data), and opportunities to submit questions to&#xD;
      cystinosis experts and to learn of clinical trial opportunities. No personal information is&#xD;
      shared outside of CCIR. Individual identities are known only to appropriate CCIR staff.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Age at treatment initiation and the effect on disease outcomes</measure>
    <time_frame>Lifetime</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Cystinosis</condition>
  <condition>Nephropathic Cystinosis</condition>
  <condition>Renal Fanconi Syndrome</condition>
  <arm_group>
    <arm_group_label>Cystinsosis patients</arm_group_label>
    <description>Those with a diagnosis of cystinosis.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        International cystinosis community&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of cystinosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry A Schneider, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Betty L Cabrera, M.P.H</last_name>
    <phone>858-822-3747</phone>
    <email>curator@cystinosisregistry.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betty L Cabrera, M.P.H.</last_name>
      <phone>619-471-9554</phone>
      <email>curator@cystinosisregistry.org</email>
    </contact>
    <investigator>
      <last_name>Jerry A Schneider, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cystinosisregistry.org</url>
    <description>CCIR Patient Portal</description>
  </link>
  <results_reference>
    <citation>Cherqui S. Cysteamine therapy: a treatment for cystinosis, not a cure. Kidney Int. 2012 Jan;81(2):127-9. doi: 10.1038/ki.2011.301.</citation>
    <PMID>22205430</PMID>
  </results_reference>
  <results_reference>
    <citation>Gangoiti JA, Fidler M, Cabrera BL, Schneider JA, Barshop BA, Dohil R. Pharmacokinetics of enteric-coated cysteamine bitartrate in healthy adults: a pilot study. Br J Clin Pharmacol. 2010 Sep;70(3):376-82. doi: 10.1111/j.1365-2125.2010.03721.x.</citation>
    <PMID>20716238</PMID>
  </results_reference>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>March 29, 2011</study_first_submitted>
  <study_first_submitted_qc>April 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2011</study_first_posted>
  <last_update_submitted>March 10, 2014</last_update_submitted>
  <last_update_submitted_qc>March 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cystinosis Research Foundation</investigator_affiliation>
    <investigator_full_name>Jerry A. Schneider</investigator_full_name>
    <investigator_title>Professor Emeritus of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Registries</keyword>
  <keyword>Cystinosis</keyword>
  <keyword>Nephropathic Cystinosis</keyword>
  <keyword>Renal Fanconi Syndrome</keyword>
  <keyword>Cystine</keyword>
  <keyword>Kidney</keyword>
  <keyword>Rare Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fanconi Syndrome</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Cystinosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

